Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?
Twelve patients with pituitary tumor whose prior treatment included surgery and radiotherapy in four, surgery alone in four, radiotherapy alone in one, and none in three were studied. Nine had hyperprolactinemia, two had elevated serum growth hormones, and one had no pituitary hormone excess. Visual field defects were present in six. All had pituitary-gonadal insufficiency manifested as impotence or amenorrhea. All were tested with bromocriptine, 7.5 to 25 mg daily, and followed up for eight to 27 (mean 15) months. Serum prolactin levels decreased to normal in seven of nine patients. Serum growth hormone values were normalized in both acromegalics. When hormone levels were reduced to normal, pituitary tumor size decreased. Vision was restored to normal in five of six patients, including one patient with pituitary tumor but no pituitary hormone excess. Bromocriptine corrects the physiological defects associated with pituitary tumors that have been incompletely treated with surgery, radiotherapy, or both and may be a useful primary treatment for patients with pituitary tumors.
D000328:Adult; D000368:Aged; D000568:Amenorrhea / Q000188:drug therapy; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011388:Prolactin / Q000097:blood; D014794:Visual Fields / Q000187:drug effects
D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone